搜索范围
M8407
应用筛选条件
关键词:'M8407'
显示 1-30 #N/A 197 条结果 关于 "M8407" 范围 论文
Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.
Josef Singer et al.
Molecular cancer therapeutics, 13(7), 1777-1790 (2014-04-24)
Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the
Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia.
Russell P Gollard et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), e327-e331 (2013-05-30)
Mette Levinsen et al.
Cancer chemotherapy and pharmacology, 75(1), 59-66 (2014-10-29)
Through enhancement of 6-mercaptopurine (6MP) bioavailability and inhibition of purine de novo synthesis, high-dose methotrexate (HD-MTX) may increase incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6MP. Patients with intermediate activity of thiopurine methyltransferase (TPMT(IA)) have higher cytosol
Christian A Waimann et al.
Arthritis and rheumatism, 65(6), 1421-1429 (2013-06-04)
To quantify adherence to oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis (RA), using electronic medication monitoring, and to evaluate the clinical consequences of low adherence. A total of 107 patients with RA enrolled in a
Reply of the authors.
Christina E Boots et al.
Fertility and sterility, 101(4), e24-e24 (2014-02-19)
Jeremy Hugh et al.
Journal of the American Academy of Dermatology, 70(1), 168-177 (2013-11-05)
Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD. We reviewed the literature to define the impact of common psoriasis therapies on cardiovascular measures and
K M Lo et al.
Biochimica et biophysica acta, 1088(2), 217-224 (1991-02-16)
We have developed an inducible system for high level expression of heterologous genes in murine hybridoma cells. The rapid induction by methotrexate (MTX) does not involve gene amplification and is controlled at the level of mRNA accumulation. Transfection was achieved
Isabel Castrejón et al.
Bulletin of the Hospital for Joint Disease (2013), 71 Suppl 1, S20-S28 (2013-11-28)
Methotrexate (MTX) is well-established as the "anchor drug" for patients with rheumatoid arthritis (RA), to be used early and aggressively, with higher long-term effectiveness, tolerability, and safety than any other disease-modifying antirheumatic drug (DMARD). However, about 20% to 40% of
Sivakumar R Rathinam et al.
Ophthalmology, 121(10), 1863-1870 (2014-06-12)
To compare the relative effectiveness of methotrexate and mycophenolate mofetil for noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Multicenter, block-randomized, observer-masked clinical trial. Eighty patients with noninfectious intermediate, posterior, or panuveitis requiring corticosteroid-sparing therapy at Aravind Eye Hospitals in Madurai
Michael E Rytting et al.
Cancer, 120(23), 3660-3668 (2014-07-22)
Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The
F M Huennekens
Advances in enzyme regulation, 34, 397-419 (1994-01-01)
Methotrexate (MTX), one of the earliest cancer chemotherapy agents, continues to be used extensively in the treatment of leukemia and a variety of other tumors. The efficacy of this drug results from its facile uptake by cells, rapid polyglutamylation and
Atsuo Tanimoto et al.
BMC musculoskeletal disorders, 16, 339-339 (2015-11-08)
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability, and decreased quality of life (QOL). Inhibition of Janus kinase (JAK) signaling ameliorates articular inflammation and joint destruction in animal models of RA, but its effects
Eric M Ruderman
Bulletin of the Hospital for Joint Disease (2013), 71 Suppl 1, S29-S32 (2013-11-28)
From the first use of biologic therapy for the management of rheumatoid arthritis, methotrexate (MTX) has been commonly used as co-therapy. There are a number of mechanistic reasons why MTX may improve the efficacy of biologics, including reduced antigenicity as
Phuong Thu Vu Hoang et al.
Journal of pediatric hematology/oncology, 36(7), 534-540 (2013-12-11)
To compare the relapse-free survival (RFS) in Vietnamese (n=141) and white (n=94) children living in Vietnam and Belgium, respectively, and treated in their own country for acute lymphoblastic leukemia according to the same FRALLE 2000 protocol. RFS was significantly worse
Koya Fushimi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(4), 449-453 (2014-04-20)
Japanese clinical trials of a tegafur/uracil(UFT)-based postoperative chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil(CMF)treatment have shown that UFT is not inferior to CMF for the treatment of hormone receptor-positive breast cancer patients. However, the usefulness of UFT for hormone
Daisy Puttevils et al.
Acta cardiologica, 69(2), 111-118 (2014-05-03)
Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 4. Macrophage activating syndrome and hemophagocytic syndrome].
Yoshinori Komagata
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 102(10), 2639-2644 (2014-01-10)
Cutaneous Rosai-Dorfman disease successfully treated with low-dose methotrexate.
Natalie Z Sun et al.
JAMA dermatology, 150(7), 787-788 (2014-05-03)
Kazuhisa Katayama et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 655-658 (2013-07-19)
Carcinomatous peritonitis may develop after operation for gastric cancer. As ascites are difficult to control, especially for gastric cancer postoperative carcinomatous peritonitis, many cases are difficult to treat. The present case was a female patient with carcinomatous peritonitis that occurred
A Perez-Delboy et al.
BJOG : an international journal of obstetrics and gynaecology, 121(2), 163-169 (2014-01-01)
Abnromalities of placentation, including placenta accreta, represent a major source of morbidity and mortality among women. Traditional management consists of peripartum hysterectomy at the time of delivery, although more conservative treatments have also been developed recently. In this review we
Hayeong Kwon et al.
Biochemical and biophysical research communications, 532(4), 535-540 (2020-09-09)
N-myristoylation is a ubiquitous protein lipidation in eukaryotes, but regulatory roles for myristoylation on proteins still remain to be explored. Here, we show that N-myristoylation of Caveolin-2 (Cav-2) controls insulin signaling. Alternative translation initiation (ATI)-yielded truncated form of non-N-myristoylable Cav-2β
Hala O El Mesallamy et al.
Journal of cancer research and clinical oncology, 140(8), 1359-1365 (2014-04-11)
High-dose methotrexate (HD-MTX) is a cornerstone antineoplastic drug in most treatment protocols of pediatric acute lymphoblastic leukemia (ALL). Among the membrane efflux transporters of MTX, the human breast cancer resistant protein is the second member of the G subfamily of
Zibin Yang et al.
International journal of clinical pharmacology and therapeutics, 52(5), 346-351 (2014-03-13)
The aim of this study was to evaluate the efficacy of methotrexate (MTX) in the treatment of ankylosing spondylitis (AS). The literature on controlled clinical trials was searched from MEDLINE, EMBASE, OVID, and Cochrane Library databases up to November 2012.
Sara Verazza et al.
Clinical and experimental rheumatology, 31(4 Suppl 78), S98-101 (2013-11-06)
Several studies have examined effects of discontinuing treatment after clinical remission in children with JIA. So far, only methotrexate and tumour necrosis factor α (TNF) inhibitors have been investigated. Overall, the relapse rate after termination of these medications was substantial.
Arjun V Balar et al.
Cancer, 121(2), 179-187 (2014-08-06)
Urothelial cancer has long been known as a chemotherapy-sensitive disease. However, clinical trial data to date suggest a plateau to the magnitude of benefit from cytotoxic therapy alone. In spite of level 1 evidence supporting cisplatin-based chemotherapy for patients with
Chen Lossos et al.
British journal of haematology, 165(5), 640-648 (2014-02-28)
Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its
Etanercept tapering in rheumatoid arthritis.
Paul Emery et al.
The New England journal of medicine, 372(5), 489-490 (2015-01-30)
Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.
T Schoffelen et al.
Annals of the rheumatic diseases, 73(7), 1436-1438 (2014-05-06)
Jun Kaneko et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(12), 2454-2456 (2014-01-08)
We report our experience with a case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient who had been treated with methotrexate (MTX) for rheumatoid arthritis for 9 consecutive years, which showed natural remission after discontinuation of the MTX therapy. The
Ajay Vora et al.
The Lancet. Oncology, 15(8), 809-818 (2014-06-14)
No randomised study has shown whether stratification of treatment by minimal residual disease (MRD) response improves outcome in children and young people with acute lymphoblastic leukaemia (ALL). We assessed whether children and young people with clinical standard and intermediate-risk ALL
1/7